Acumen pharmaceuticals to present during international conference on alzheimer's and parkinson's diseases 2025 and american academy of neurology annual meeting

Oral presentations will highlight the implementation of a validated research-use plasma ptau217 assay in the participant screening process for the phase 2 altitude-ad study of sabirnetug oral presentations will highlight the implementation of a validated research-use plasma ptau217 assay in the participant screening process for the phase 2 altitude-ad study of sabirnetug
ABOS Ratings Summary
ABOS Quant Ranking